Certara, Paidion Research partner on pediatric drug development
Certara, a global biosimulation technology-enabled drug development company, and Paidion Research, a Durham, N.C.-based pediatric CRO, have partnered to promote more efficient and reliable drug development for pediatric patients. The partnership harnesses Certara’s biosimulation (modeling and simulation) and regulatory writing capabilities with Paidion’s regulatory strategy and pediatric clinical trial management expertise to address the critical challenges of bringing new therapies to children.
“The FDA reports that pediatric product development initiatives have resulted in improved product labeling, increased identification of adverse events, and the development of new pediatric formulations. However, 42% of recent pediatric trials have failed to establish either safety or efficacy,” said Certara Chief Executive Officer Edmundo Muniz, M.D., Ph.D. “Both Certara and Paidion are passionate in their scientific commitment to developing safer medicines for children, as they are our most precious resource.”
Paidion CEO Barry Mangum, PharmD, FCP, added, “Sick children represent the most vulnerable population in the world. As our understanding of pediatric patients has grown, we recognize that they manifest many diseases and side effects of the related medical treatments differently than adults. Combining Certara’s expertise in both pharmacokinetic/pharmacodynamic (PK/PD) and physiologically-based PK (PBPK) modeling with Paidion’s success rate in conducting pediatric clinical trials will be transformative.”
Both the FDA and the EMA have legislated that pharmaceutical companies must develop label guidelines for pediatric drug development. This requirement has resulted in an increased need for new scientific approaches, a clear aim of the Certara/Paidion partnership.
One of the greatest challenges in pediatric clinical research is defining a safe and effective dose or dose range for this patient population that can span premature neonates to adolescents. There are significant physiological differences between children and adults that can affect the absorption, distribution, metabolism, and elimination (ADME) of medications. Certara has developed specific technologies and strategies to inform proper dose selection, including PK/PD simulations using sparse data analysis and its Simcyp Pediatric PBPK simulator. The simulator captures changes in physiology and enzyme/transporter development that are particularly prominent in children from birth to two years of age. The Simcyp Simulator is used by many pharmaceutical companies and international regulatory agencies. In 2012, FDA voted unanimously in support of extending the use of PBPK modeling for pediatric drug development.
In addition to physiological differences between pediatric populations, there are sizeable challenges in conducting pediatric clinical trials, which include study design, patient identification, recruitment and retention, and determining clinical benchmarks. The available pool of pediatric populations for many target indications is much smaller than adults, and ethical constraints signiﬁcantly limit the number of participants. Paidion’s pediatric focus, as well as its formation of sustainable neonatal and pediatric intensive care unit and pediatric clinical site networks, will help resolve those challenges.
Current FDA and EMA guidelines recommend that dose selection for pediatric studies be based on all available prior information, starting with what has been learned in adult populations. This guidance translates into an ethical imperative to use biosimulation to inform pediatric drug development whenever possible, minimizing the impact on children that must enroll in clinical trials. At the same time, clinical trials are still a necessary part of drug development and they must be organized with a pediatric patient-centric focus. By combining expertise in biosimulation, pediatric clinical trial management, and regulatory strategy and writing, the Certara/Paidion partnership intends to greatly expand the number of new medications available to children.